But should Sanofi gain acceptance from enough Genzyme shareholders—especially if, as expected, it boosts its offer—it could become more difficult for Genzyme's board to withhold its approval. And in a conference call with analysts Monday, Mr. Viehbacher didn't rule out the possibility of ultimately seeking to oust Genzyme's board.